Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor.

12 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

New molecular test kit predicts survival outcomes in kidney cancer patients

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients. This breakthrough was recently reported in European Urology, the world's top urology journal.

4 Aug 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.

25 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.

25 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo.

22 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

22 Jul 2014

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest.

22 Jul 2014

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.

14 Jul 2014

Research into cell metabolism could open new therapeutic avenues for diabetes, cancer

More scientific research into the metabolism of stromal support cells and immune cells - and the role of the metabolism of these cell types in the development of diseases - could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature.

10 Jul 2014

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

7 Jul 2014

Researchers discover mechanical threshold that regulates angiogenesis

Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is essential to the body's development. As organs grow, vascular networks must grow with them to feed new cells and remove their waste.

4 Jul 2014

Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida.

2 Jul 2014

Metabolic pathway genes linked to AMD and choroidal vasculopathy

The cholesteryl ester transfer protein gene appears to increase susceptibility to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy, research shows.

1 Jul 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

NIH receives $10 million grant for research on breast cancer metastasis

The American Cancer Society predicts that 40,000 American women will die from breast cancer this year. Most of those deaths will occur due to cells from the primary tumor that spread to other parts of the body-the process known as metastasis.

20 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Researchers discover crucial process that regulates development of blood vessels

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels.

19 Jun 2014

Angiogenesis News and Research

Further Reading

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

New molecular test kit predicts survival outcomes in kidney cancer patients

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

Researchers create combination drug that controls both tumor growth and metastasis

Research into cell metabolism could open new therapeutic avenues for diabetes, cancer

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Researchers discover mechanical threshold that regulates angiogenesis

Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

Metabolic pathway genes linked to AMD and choroidal vasculopathy

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

NIH receives $10 million grant for research on breast cancer metastasis

New treatment for ovarian cancer can improve response rates

Researchers discover crucial process that regulates development of blood vessels

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo